“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

Add Yahoo as a preferred source to see more of our stories on Google. Thousands of men suffering from prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Add Yahoo as a preferred source to see more of our stories on Google. A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, experts have said. The treatment, a ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Thousands of men with prostate cancer are set to get a life-extending drug on the NHS within weeks – in a breakthrough that could give families precious extra years together. For the first time, ...

Taking one-fourth the standard dose of a widely used drug for prostate cancer with a low-fat breakfast can be as effective - and four times less expensive - as taking the standard dose as recommended: ...

Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...